Chicago, Sept. 29, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026", is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7%. Rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the influenza diagnostics market.
Browse and in-depth TOC on "Influenza Diagnostics Market" 154- Tables 41- Figures 193- Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=222985562
The Growth in influenza research for diagnostic technologies, increasing prevalence of influenza and rising demand for rapid disease diagnosis are the major factors driving the influenza diagnostic market’s growth.
Based on products, the influenza diagnostics market is segmented into test kits and reagents, instruments and other products. In 2020, the test kits and reagents segment accounted for the largest share of the market, mainly due to Rising demand for rapid disease diagnosis and growth in influenza research for diagnostic technologies.
Based on test type, the influenza diagnostics market is segmented into traditional diagnostic test (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests) and molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests(transcription-mediated amplification-based assay, loop-mediated isothermal amplification-based assay, nucleic acid sequence-based amplification tests, other isothermal nucleic acid amplification tests) and other molecular diagnostic tests). In 2020, the molecular diagnostic tests segment accounted for the largest share of the market. The large share of this segment can mainly be attributed to the increasing prevalence of influenza and growth in influenza research for diagnostic technologies.
Based on end users, the influenza diagnostics market has been segmented into diagnostic laboratories, hospitals and clinics and other end users. In 2020, the diagnostic laboratories segment accounted for the largest share of market, mainly due to the increasing prevalence of influenza and rising demand for rapid disease diagnosis.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222985562
The global influenza diagnostics market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest regional market for market in 2020. The large share of North America in this market can be attributed to the growth in influenza research for diagnostic technologies in the country and increasing prevalence of influenza.
The major players operating in this influenza diagnostics market are Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecanclinica Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada). Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=222985562
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) (2022 - 2027)
Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027
David Trainer, the CEO of the investment research firm New Constructs, believes there are now roughly 300 publicly-traded zombie companies.
The bear market in software stocks has already lasted far longer than the typical decline, according to MoffettNathanson,
Inflation, interest rates, and recession – these are the bogeymen of investing, and they’ve been watching over our shoulders for the past several months. We all know the story by now, the rate of inflation is running at generational highs, the Federal Reserve is hiking rates in an attempt to push back against high prices, and that’s likely to tip the economy into recession. At a time like this, investors are showing a growing interest in finding strong defensive portfolio moves. It’s a mindset t
Overwhelming bearishness means stocks are reflecting "draconian earnings,” says David Baron of Baron Focused Growth.
Semiconductor stocks have tumbled in recent months amid flagging demand, with the S&P Semiconductors Select Industry Index dropping 36% year to date. Bank of America analysts recently discussed their favorite choices in the sector.
It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.
The bears are running rampant on Wall Street. Of the 43 analysts surveyed by Refinitiv that cover Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL), 38 of them rate the tech stock as a buy or strong buy. It's not surprising, therefore, that Wall Street's consensus 12-month price target reflects a 47% upside potential.
Geopolitical risks remain high. Prepare.
Yes, Carnival reported a bigger-than-expected loss but in this case, unlike taking a cruise, it's the destination not the journey for the cruise lines.
You've got to hand it to Robinhood investors. They're not letting an ugly start to the year for the S&P 500 scare them.
(Bloomberg) -- Spiraling losses on Wall Street are now snowballing into forced asset liquidation, according to Bank of America Corp. strategists. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandTop Apple Executive Is Leaving After Making Crude Remarks in TikTok VideoMeta to Cut Headcount for First Time, Slash Budgets Across TeamsMarjorie Taylor Greene’s Husband Files for Divorce After 27 YearsPutin Says Annexation Is Forever, Defends Ukraine Land GrabThe NYS
See who joins GOOGL and MSFT on this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.
These top-tier companies are begging to be bought following a 34% peak decline in the Nasdaq Composite.
Intel Corporation (NASDAQ:INTC) started an accelerated downtrend in August. The company lost 27% of its market value since then, and investors may be concerned about the near future. Looking at analysts forecasts, it seems that there may be some more pain ahead. We break down the fundamentals, future expectations, and see what that means for investors in our analysis.
The stock market desperately wants to put in a low. The Federal Reserve won’t let it. On the one hand, U.S. economic data remains strong, as jobless claims fell below 200,000 for the first time since May, a sign that the Fed will have to keep raising interest rates to slow down inflation.